 Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies Strong royalty growth with PolyXen platform technology Bolstered cash position with recently completed 12.5 million private placement FRAMINGHAM, MA ACCESSWIRE August 13, 2021 Xenetic Biosciences, Inc. NASDAQ:XBIO Xenetic or the Company, a biopharmaceutical company focused on advancing XCARTTM, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the second quarter of 2021 and provided a corporate update. Over the course of the second quarter, we continued to execute our innovative and differentiated XCART program, and the technical progress weve accomplished brings us closer to the critical milestone of conducting IND-enabling studies in the United States. 